




Searching News Database: dyslipidemia
HSMN NewsFeed - 4 Nov 2021
NeuroBo Pharmaceuticals Appoints Gil Price, M.D. as President and Chief Executive Officer
NeuroBo Pharmaceuticals Appoints Gil Price, M.D. as President and Chief Executive Officer
HSMN NewsFeed - 2 Sep 2020
NeuroBo Pharmaceuticals Appoints Douglas J. Swirsky to the Board of Directors
NeuroBo Pharmaceuticals Appoints Douglas J. Swirsky to the Board of Directors
HSMN NewsFeed - 13 Mar 2020
EMD Serono and Pfizer Provide Update on Phase III JAVELIN Head and Neck 100 Study
EMD Serono and Pfizer Provide Update on Phase III JAVELIN Head and Neck 100 Study
HSMN NewsFeed - 22 Feb 2017
Repatha(R) (Evolocumab) Receives European Commission Approval For New 420 mg Single-Dose Delivery Option
Repatha(R) (Evolocumab) Receives European Commission Approval For New 420 mg Single-Dose Delivery Option
HSMN NewsFeed - 1 Nov 2016
Pfizer Discontinues Global Development of Bococizumab, Its Investigational PCSK9 Inhibitor
Pfizer Discontinues Global Development of Bococizumab, Its Investigational PCSK9 Inhibitor
HSMN NewsFeed - 1 Aug 2016
Orexigen Completes Acquisition of All U.S. Rights to Contrave(R) and Launches U.S. Sales Organization
Orexigen Completes Acquisition of All U.S. Rights to Contrave(R) and Launches U.S. Sales Organization
HSMN NewsFeed - 8 Jun 2016
Orexigen Therapeutics Reports Favorable Markman Ruling in Contrave(R) Patent Litigation
Orexigen Therapeutics Reports Favorable Markman Ruling in Contrave(R) Patent Litigation
HSMN NewsFeed - 16 Oct 2015
Daiichi Sankyo, Inc. Reorganizes its U.S. Commercial Operations to Support Upcoming Specialty Pipeline
Daiichi Sankyo, Inc. Reorganizes its U.S. Commercial Operations to Support Upcoming Specialty Pipeline
HSMN NewsFeed - 30 Sep 2015
J. Robert Paulson and Jeffrey Mathiesen Appointed to Sun BioPharma Board of Directors
J. Robert Paulson and Jeffrey Mathiesen Appointed to Sun BioPharma Board of Directors
HSMN NewsFeed - 12 Jun 2015
FDA Approves Promacta(R) for New Pediatric Chronic Immune Thrombocytopenia (cITP) Indication
FDA Approves Promacta(R) for New Pediatric Chronic Immune Thrombocytopenia (cITP) Indication
HSMN NewsFeed - 19 Mar 2015
Daiichi Sankyo Signs Agreement With AstraZeneca To Co-Commercialize MOVANTIK In The US
Daiichi Sankyo Signs Agreement With AstraZeneca To Co-Commercialize MOVANTIK In The US
HSMN NewsFeed - 14 Aug 2014
Ligand Signs Multi-Program Captisol(R) License Agreement with Avion Pharmaceuticals
Ligand Signs Multi-Program Captisol(R) License Agreement with Avion Pharmaceuticals
HSMN NewsFeed - 6 May 2014
FDA Approves EPANOVA for the Treatment of Adults with Severe Hypertriglyceridemia
FDA Approves EPANOVA for the Treatment of Adults with Severe Hypertriglyceridemia
HSMN NewsFeed - 20 Sep 2013
Teva Announces Exclusive Launch of Generic NIASPAN(R) in the United States
Teva Announces Exclusive Launch of Generic NIASPAN(R) in the United States
HSMN NewsFeed - 26 Jul 2013
Ligand Receives Orphan Designation for Captisol-Enabled(TM) Topiramate Injection
Ligand Receives Orphan Designation for Captisol-Enabled(TM) Topiramate Injection
HSMN NewsFeed - 22 Oct 2012
DARA BioSciences Launches Soltamox(R), First and Only Liquid Version of Tamoxifen Citrate
DARA BioSciences Launches Soltamox(R), First and Only Liquid Version of Tamoxifen Citrate
HSMN NewsFeed - 7 Feb 2012
Ligand Names Nishan de Silva, M.D., Vice President of Corporate Development
Ligand Names Nishan de Silva, M.D., Vice President of Corporate Development
HSMN NewsFeed - 23 Dec 2011
VIVUS Announces Date of FDA Advisory Committee Review of Qnexa for the Treatment of Obesity
VIVUS Announces Date of FDA Advisory Committee Review of Qnexa for the Treatment of Obesity
HSMN NewsFeed - 10 Oct 2011
Ligand Enters Into Global Licensing Agreement With Chiva Pharmaceuticals for Fablyn(R)
Ligand Enters Into Global Licensing Agreement With Chiva Pharmaceuticals for Fablyn(R)
HSMN NewsFeed - 28 Jul 2011
Ramona M. Lloyd, Ph.D., RAC, Joins Omthera Pharmaceuticals as Vice President Regulatory Affairs
Ramona M. Lloyd, Ph.D., RAC, Joins Omthera Pharmaceuticals as Vice President Regulatory Affairs
HSMN NewsFeed - 14 Mar 2011
Omthera Pharmaceuticals Raises $33.9 Million in Series B Funding Led by New Enterprise Associates
Omthera Pharmaceuticals Raises $33.9 Million in Series B Funding Led by New Enterprise Associates
HSMN NewsFeed - 3 Feb 2011
Theratechnologies and Ferrer Announce a Distribution & Licensing Agreement for Tesamorelin in Europe
Theratechnologies and Ferrer Announce a Distribution & Licensing Agreement for Tesamorelin in Europe
HSMN NewsFeed - 31 Jan 2011
Baxter Introduces OLIMEL in Canada as the First Triple-Chamber Bag for Nutrition
Baxter Introduces OLIMEL in Canada as the First Triple-Chamber Bag for Nutrition
HSMN NewsFeed - 20 Dec 2010
VIVUS Files European Marketing Authorization Application for QNEXA(R) in the Treatment of Obesity
VIVUS Files European Marketing Authorization Application for QNEXA(R) in the Treatment of Obesity
HSMN NewsFeed - 17 Aug 2010
Amarin Corporation Appoints Colin W. Stewart as President and Chief Executive Officer
Amarin Corporation Appoints Colin W. Stewart as President and Chief Executive Officer
HSMN NewsFeed - 29 Jul 2010
Abbott's SIMCOR(R) (niacin extended-release / simvastatin) Receives FDA Approval for New Dosage Strengths
Abbott's SIMCOR(R) (niacin extended-release / simvastatin) Receives FDA Approval for New Dosage Strengths
HSMN NewsFeed - 7 Apr 2010
Recordati Signs Co-Marketing Agreement With Esteve in Spain for Pitavastatin
Recordati Signs Co-Marketing Agreement With Esteve in Spain for Pitavastatin
HSMN NewsFeed - 11 Feb 2010
Daiichi Sankyo, Inc. Names Dr. Jay Feingold Vice President, Medical Affairs
Daiichi Sankyo, Inc. Names Dr. Jay Feingold Vice President, Medical Affairs
HSMN NewsFeed - 11 Feb 2010
FDA Approves Benicar(R) for the Treatment of High Blood Pressure in Children and Adolescents aged 6-16
FDA Approves Benicar(R) for the Treatment of High Blood Pressure in Children and Adolescents aged 6-16
HSMN NewsFeed - 18 Jan 2010
Theratechnologies Reports Date for FDA Advisory Committee Review of the Tesamorelin New Drug Application
Theratechnologies Reports Date for FDA Advisory Committee Review of the Tesamorelin New Drug Application
HSMN NewsFeed - 29 Dec 2009
VIVUS Submits Qnexa(R) New Drug Application to the FDA for the Treatment of Obesity
VIVUS Submits Qnexa(R) New Drug Application to the FDA for the Treatment of Obesity
HSMN NewsFeed - 23 Dec 2009
Lilly, Kowa and Kowa Pharmaceuticals America Announce Co-Promotion and Licensing Agreement
Lilly, Kowa and Kowa Pharmaceuticals America Announce Co-Promotion and Licensing Agreement
HSMN NewsFeed - 2 Dec 2009
Amarin Corporation Appoints Industry Veteran Joseph Zakrzewski as Executive Chairman
Amarin Corporation Appoints Industry Veteran Joseph Zakrzewski as Executive Chairman
HSMN NewsFeed - 4 Aug 2009
FDA Approves LIVALO(R) for Primary Hypercholesterolemia and Combined Dyslipidemia
FDA Approves LIVALO(R) for Primary Hypercholesterolemia and Combined Dyslipidemia
HSMN NewsFeed - 4 Jun 2009
Abbott and AstraZeneca Extend Relationship to Include Co-Promotion of TRILIPIX(R) (fenofibric acid)
Abbott and AstraZeneca Extend Relationship to Include Co-Promotion of TRILIPIX(R) (fenofibric acid)
HSMN NewsFeed - 13 May 2009
AZOR(R) Receives FDA Approval as First-Line Treatment for High Blood Pressure
AZOR(R) Receives FDA Approval as First-Line Treatment for High Blood Pressure
HSMN NewsFeed - 7 May 2009
Results From Phase 3 EQUATE Trial of VIVUS' Qnexa Highlighted at European Congress on Obesity
Results From Phase 3 EQUATE Trial of VIVUS' Qnexa Highlighted at European Congress on Obesity
HSMN NewsFeed - 6 Nov 2008
FDA Approves Additional Indication for Norditropin(R) for Small for Gestational Age (SGA) in Children
FDA Approves Additional Indication for Norditropin(R) for Small for Gestational Age (SGA) in Children
HSMN NewsFeed - 4 Nov 2008
FDA Approves Additional Indication for Norditropin(R) for Small for Gestational Age (SGA) in Children
FDA Approves Additional Indication for Norditropin(R) for Small for Gestational Age (SGA) in Children
HSMN NewsFeed - 14 Aug 2008
Abbott and AstraZeneca Expand Relationship to Include Co-Promotion of CRESTOR(R)
Abbott and AstraZeneca Expand Relationship to Include Co-Promotion of CRESTOR(R)
HSMN NewsFeed - 14 Jul 2008
Cortria Corporation Announces Appointment of Daniel Grau as CEO & Vice-Chairman and Richard King as Director
Cortria Corporation Announces Appointment of Daniel Grau as CEO & Vice-Chairman and Richard King as Director
HSMN NewsFeed - 28 Apr 2008
Merck Receives Not Approvable Letter from FDA for MK-0524A (ER niacin/laropiprant)
Merck Receives Not Approvable Letter from FDA for MK-0524A (ER niacin/laropiprant)
HSMN NewsFeed - 21 Jan 2008
Welchol(TM) (colesevelam HCl) Receives FDA Approval to Reduce Blood Glucose in Adults With Type 2 Diabetes
Welchol(TM) (colesevelam HCl) Receives FDA Approval to Reduce Blood Glucose in Adults With Type 2 Diabetes
HSMN NewsFeed - 19 Jan 2008
Welchol(TM) (colesevelam HCl) Receives FDA Approval to Reduce Blood Glucose in Adults with Type 2 Diabetes
Welchol(TM) (colesevelam HCl) Receives FDA Approval to Reduce Blood Glucose in Adults with Type 2 Diabetes
HSMN NewsFeed - 16 Jan 2008
VIA Pharmaceuticals Names Rebecca Taub Senior Vice President of Research and Development
VIA Pharmaceuticals Names Rebecca Taub Senior Vice President of Research and Development
HSMN NewsFeed - 1 Oct 2007
Theratechnologies Reports Positive 52-Week Phase 3 Results for its Lead Drug Candidate Tesamorelin
Theratechnologies Reports Positive 52-Week Phase 3 Results for its Lead Drug Candidate Tesamorelin
HSMN NewsFeed - 21 Aug 2007
Daiichi Sankyo and Forest Laboratories Sign Letter of Intent for Co-Promotion of AZOR(TM)
Daiichi Sankyo and Forest Laboratories Sign Letter of Intent for Co-Promotion of AZOR(TM)
HSMN NewsFeed - 24 Jul 2007
Cerenis Therapeutics Announces the Addition of Three Pharmaceutical Industry Veterans to its Management Team
Cerenis Therapeutics Announces the Addition of Three Pharmaceutical Industry Veterans to its Management Team
HSMN NewsFeed - 3 May 2007
Metabolex Names Charpentier to the Post of Vice President for Regulatory Affairs
Metabolex Names Charpentier to the Post of Vice President for Regulatory Affairs
HSMN NewsFeed - 20 Apr 2007
Abbott Submits New Drug Application for Combination Niaspan(R)/Simvastatin Tablet
Abbott Submits New Drug Application for Combination Niaspan(R)/Simvastatin Tablet
HSMN NewsFeed - 28 Mar 2007
Daiichi Sankyo, Inc. Announces Filing For WelChol Label Change to Include Ezetimibe Efficacy Data
Daiichi Sankyo, Inc. Announces Filing For WelChol Label Change to Include Ezetimibe Efficacy Data
HSMN NewsFeed - 31 Jan 2007
Theratechnologies Launches Confirmatory Phase 3 Trial Testing TH9507 in HIV-Associated Lipodystrophy
Theratechnologies Launches Confirmatory Phase 3 Trial Testing TH9507 in HIV-Associated Lipodystrophy
HSMN NewsFeed - 13 Nov 2006
WelChol and Ezetimibe Combination Therapy Provides Significant LDL-C Reductions
WelChol and Ezetimibe Combination Therapy Provides Significant LDL-C Reductions
HSMN NewsFeed - 6 Nov 2006
Abbott to Expand Presence in Lipid Management Market With Acquisition of Kos Pharmaceuticals
Abbott to Expand Presence in Lipid Management Market With Acquisition of Kos Pharmaceuticals
HSMN NewsFeed - 25 Sep 2006
Arena Pharmaceuticals Announces Update on Partnership With Merck in Development of Niacin Receptor Agonists
Arena Pharmaceuticals Announces Update on Partnership With Merck in Development of Niacin Receptor Agonists
HSMN NewsFeed - 12 Jul 2006
Kos Submits Supplemental New Drug Application To FDA For New Niaspan(R) CF Range of Products
Kos Submits Supplemental New Drug Application To FDA For New Niaspan(R) CF Range of Products
Additional items found! 77

Members Archive contains
77 additional stories matching:
dyslipidemia
(Password required)
dyslipidemia
(Password required)